VLS Valneva SE

VALNEVA - Declaration of shares and voting rights: May 31, 2023

VALNEVA - Declaration of shares and voting rights: May 31, 2023

VALNEVA

Declaration of shares and voting rights

May 31, 2023

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: June 7, 2023

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the changeDate on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 



138,896,600



ordinary shares with a par value of €0.15 each
161,012,263 



Double voting rights granted on 7,355 ordinary shares



 



Conversion of 549,632 free ordinary shares into ordinary shares



 



Transfer of 10 shares with double voting rights into bearer form



 



Sale of 500,000 shares with double voting rights



 
Between May 3 & May 31, 2023



 



May 10, 2023



 



May 12, 2023



 



Between May 25 & May 30, 2023



 
160,887,941

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
07/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE

VALNEVA Declaration of shares and voting rights: February 28, 2026

VALNEVA Declaration of shares and voting rights: February 28, 2026 VALNEVA Declaration of shares and voting rights February 28, 2026__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 LyonRegulated market of Euronext Paris - Compartment B Declaration date: March 6, 2026 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this c...

 PRESS RELEASE

VALNEVA Déclaration d’actions et de droits de vote : 28 février 2026

VALNEVA Déclaration d’actions et de droits de vote : 28 février 2026 VALNEVA Déclaration d’actions et de droits de vote 28 février 2026__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon Marché réglementé Euronext Paris - Compartiment B Date de la déclaration : 6 mars 2026 Nombre d’actions composant le capital de ValnevaNombre total de droits de vote incluant les droits de vote suspendus*Origine de la variation...

 PRESS RELEASE

Valneva annonce sa participation à des conférences investisseurs

Valneva annonce sa participation à des conférences investisseurs  Lyon (France), le 2 mars 2026 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante feront des présentations et participeront à des rendez-vous avec des investisseurs institutionnels lors de prochaines conférences aux États-Unis et en Europe. Thomas Lingelbach, directeur général, et Peter Bühler, directeur financier, feront un point sur les principaux éléments de création de valeur de la Société ainsi que les catalyseurs attendus, dont les...

 PRESS RELEASE

Valneva to Participate in Upcoming Investor Conferences

Valneva to Participate in Upcoming Investor Conferences Lyon (France), March 2, 2026 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach and CFO Peter Buhler will discuss the Company’s key value drivers and upcoming catalysts, including the topline Phase 3 data readout for VLA15, the Company’s Lyme disease vaccine candidate, which partner Pfizer expects to report in the first half of 2026. The TD Cowen presenta...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch